share_log

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga ·  Oct 25 04:31

Gainers

  • Bionomics (NASDAQ:BNOX) shares rose 48.3% to $0.53 during Thursday's after-market session. The market value of their outstanding shares is at $7.0 million.
  • Lyell Immunopharma (NASDAQ:LYEL) stock moved upwards by 32.92% to $1.45. The company's market cap stands at $370.9 million.
  • Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 9.64% to $1.25. The market value of their outstanding shares is at $41.3 million.
  • OneMedNet (NASDAQ:ONMD) shares increased by 8.74% to $0.87. The company's market cap stands at $20.7 million.
  • Edwards Lifesciences (NYSE:EW) shares increased by 7.32% to $75.5. The market value of their outstanding shares is at $45.4 billion. As per the press release, Q3 earnings came out today.
  • Impact BioMedical (AMEX:IBO) stock increased by 6.85% to $1.87. The market value of their outstanding shares is at $21.5 million.

Losers

  • DexCom (NASDAQ:DXCM) stock declined by 15.2% to $63.5 during Thursday's after-market session. The company's market cap stands at $25.4 billion. The company's, Q3 earnings came out today.
  • Quince Therapeutics (NASDAQ:QNCX) stock declined by 14.29% to $1.02. The market value of their outstanding shares is at $44.1 million.
  • Universal Health Servs (NYSE:UHS) shares declined by 10.98% to $200.0. The company's market cap stands at $13.3 billion. As per the press release, Q3 earnings came out today.
  • Allakos (NASDAQ:ALLK) stock decreased by 6.65% to $1.11. The market value of their outstanding shares is at $98.7 million.
  • Catheter Precision (AMEX:VTAK) stock fell 6.34% to $0.82. The market value of their outstanding shares is at $2.2 million.
  • Scorpius Holdings (AMEX:SCPX) shares fell 5.55% to $0.71. The market value of their outstanding shares is at $2.2 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment